Ranbaxy Board declares change in executive leadership

Our News BureauMumbai

Ranbaxy Laboratories announced that Atul Sobti will step down from the positions of Chief Executive Officer (CEO) and Managing Director (MD) of Ranbaxy, effective August 19, 2010 and Arun Sawhney, currently Ranbaxy’s President, Global Pharmaceutical Business, has been appointed as Managing Director, effective from August 20, 2010.

Furthermore, the board noted its sincere appreciation of Sobti’s efforts during his tenure as CEO and MD as well as for building upon the strong legacy of Ranbaxy as a premier global company.

Commenting on these changes, Dr Tsutomu Une, Ranbaxy Chairman said, “We are extremely grateful for the significant contribution Sobti has made to Ranbaxy ever since he joined the company. Under his leadership as CEO and MD, Ranbaxy has realised various opportunities to repeat the strong operating performance while continuing to manage key challenges.” Une also said, “We are pleased to appoint Sawhney as the MD further advancing the company with the decades of global experience he has in the industry.”

Sawhney, with over three decades of global experience with leading Indian and global pharma companies has held the role of President, Global Pharmaceuticals Business, at Ranbaxy, since January 2010, and has been a senior executive at the company from April 2008, providing leadership in diverse functions to achieve optimum synergy to facilitate the business objectives of the organisation. Sawhney is one of the founder members of the Pharmaceuticals Export Promotion Council (Pharmexcil) and has been an active member on the committees of the prestigious Indian Drug Manufacturer’s Association and Bulk Drug Manufacturers Association (India).